Insights on the North American Monoclonal Antibodies Market to 2026 | Industry Statistics, Emerging Demands, Forecast to 2026

North American monoclonal antibodies market is estimated to grow at a CAGR of 6.8% during the forecast period. An increasing trial of monoclonal antibodies for COVID-19 has been reported in the region. As per the National Institutes of Health (NIH), monoclonal antibodies could act as vital components for the response to the COVID-19 outbreak till vaccines become available as it may provide short-term protection from SARS-CoV-2. In August 2020, GlaxoSmithKline plc and Vir Biotechnology, Inc. declared the first dose in phase II/III study with VIR-7831 (also referred to as GSK4182136). It is a completely human anti-SARS-CoV-2 monoclonal antibody (Severe Acute Respiratory Syndrome coronavirus-2). This is indicated for the early treatment of COVID-19 among patients at high risk of hospitalization. 

To Request a Sample of our Report on North American Monoclonal Antibodies Market:  https://www.omrglobal.com/request-sample/north-american-monoclonal-antibodies-market

Additionally, in August 2020, the National Institutes of Health (NIH) introduced a clinical trial that aims to test antibody therapy in hospitalized COVID-19 patients. Under the trial, COVID-19 patients at selected hospitals can volunteer in a clinical trial intended to test the efficacy and safety of an effective novel treatment for COVID-19. It is a Phase 3 randomized, controlled trial which is referred to as ACTIV-3, and as a master protocol. This is designed to test several diverse kinds of monoclonal antibody therapies. 

Scope of the North American Monoclonal Antibodies Market

Market Coverage

·        Market number available for 2019-2026

·        Base year- 2019

·        Forecast period- 2020-2026

·        Segment Covered- By Source and Application

·        Regions Covered- US and Canada

·        Competitive Landscape- Amgen Inc., Eli Lilly & Co., Pfizer Inc., Merck & Co., Inc., and F. Hoffman La-Roche AG

Recent Strategic Initiatives in the North American Monoclonal Antibodies Market

·        In December 2019, Mylan N.V. and Biocon Ltd. declared the US FDA launch of Ogivri (trastuzumab-dkst). It is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer. 

·        In January 2020, Pfizer launched three new biosimilars named rituximab-pvvr (Ruxience), trastuzumab-qyyp (Trazimera), and bevacizumab-bvzr (Zirabev) in the US. This is expected that the specialty drugs will be launched at the lowest wholesale acquisition cost (WAC) among trastuzumab, bevacizumab, or rituximab products currently on the market. These drugs will become available at a discounted price than their equivalents brand name. This launch can support significant savings for the healthcare system in the US while enhancing access to vital therapies. 

(Get 15% Discount on Buying this Report)

A full Report of North American Monoclonal Antibodies Market is Available at:  https://www.omrglobal.com/industry-reports/north-american-monoclonal-antibodies-market

North American Monoclonal Antibodies Market-Segmentation

By Source

·        Murine

·        Chimeric

·        Human

·        Humanized

By Application

·        Cancer

·        Infectious Diseases

·        Auto-Immune Diseases

·        Inflammatory Diseases

·        Others

North American Monoclonal Antibodies Market– Segment by Country

·        US

·        Canada

Company Profiles

·        AbbVie Inc.

·        Amgen Inc.

·        Aytu BioScience, Inc.

·        Biocon Ltd.

·        Bristol Myers Squibb Co.

·        Eli Lilly and Co.

·        F. Hoffman La-Roche AG

·        Gilead Sciences, Inc.

·        Johnson & Johnson Services, Inc.

·        Merck & Co., Inc.

·        Mylan N.V.

·        Oncologie, Inc.

·        Pfizer Inc.

·        Spectrum Pharmaceuticals, Inc.

Reasons to buy from us –

1.  We cover more than 15 major industries, further segmented into more than 90 sectors.

2.  More than 120 countries are for analysis.

3.  Over 100+ paid data sources mined for investigation.

4.  Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @  https://www.omrglobal.com/report-customization/north-american-monoclonal-antibodies-market

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404